

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A substantially pure ~~Substantially purified form of the~~ polypeptide ~~that comprising~~ (a) a polypeptide having the amino acid sequence of shown in SEQ ID NO: NOS. 1, 4, 7, 10 or 13, (b) a polypeptide having at least 90% sequence homology over the entire length of the amino acid sequence of SEQ ID NO: 7 ~~homologue thereof,~~ or (c) a fragment thereof of the polypeptide having the amino acid sequence of SEQ ID NO: 7, or homologue of the fragment, wherein said polypeptides of (a) and (b), and said fragment of (c), have anti-inflammatory activity.

2. (currently amended) The ~~A~~ polypeptide according to claim 1, wherein said polypeptide comprises ~~that comprising the~~ amino acid ~~amino acid~~ sequence of shown in SEQ ID NO: S. 1, 4, 7, 10 or 13.

3.-9. (cancelled).

10. (currently amended) A pharmaceutical composition comprising a ~~containing the~~ polypeptide according to claim 1 or 2 ~~or the antibody according to claim 9,~~ in association with pharmaceutically acceptable diluent and/or carrier.